{"id":"https://openalex.org/W2743545796","doi":"https://doi.org/10.21693/1933-088x-15.4.193","title":"Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape","display_name":"Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape","publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W2743545796","doi":"https://doi.org/10.21693/1933-088x-15.4.193","mag":"2743545796"},"language":"en","primary_location":{"id":"doi:10.21693/1933-088x-15.4.193","doi":"https://doi.org/10.21693/1933-088x-15.4.193","is_oa":true,"landing_page_url":"https://doi.org/10.21693/1933-088x-15.4.193","pdf_url":null,"source":{"id":"https://openalex.org/S4210197088","display_name":"Advances in Pulmonary Hypertension","issn_l":"1933-088X","issn":["1933-088X","1933-0898"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Pulmonary Hypertension","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.21693/1933-088x-15.4.193","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078732560","display_name":"Robert P. Frantz","orcid":"https://orcid.org/0000-0003-4128-3978","observed_orcids":["https://orcid.org/0000-0003-4128-3978"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert P. Frantz","raw_affiliation_strings":["Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5078732560"],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.15261006,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"15","issue":"4","first_page":"193","last_page":"197"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10728","display_name":"Pulmonary Hypertension Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10728","display_name":"Pulmonary Hypertension Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12199","display_name":"Vascular Anomalies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pulmonary-arterial-hypertension","display_name":"pulmonary arterial hypertension","score":0.9919999837875366},{"id":"https://openalex.org/keywords/riociguat","display_name":"riociguat","score":0.9819999933242798},{"id":"https://openalex.org/keywords/selexipag","display_name":"selexipag","score":1.0},{"id":"https://openalex.org/keywords/oral-treprostinil","display_name":"oral treprostinil","score":0.9779999852180481},{"id":"https://openalex.org/keywords/soluble-guanylate-cyclase-stimulator","display_name":"soluble guanylate cyclase stimulator","score":0.8759999871253967},{"id":"https://openalex.org/keywords/prostacyclin-receptor-agonist","display_name":"prostacyclin receptor agonist","score":0.9789999723434448},{"id":"https://openalex.org/keywords/phosphodiesterase-5-inhibitors","display_name":"phosphodiesterase-5 inhibitors","score":0.949999988079071},{"id":"https://openalex.org/keywords/endothelin-receptor-antagonists","display_name":"endothelin receptor antagonists","score":0.9959999918937683},{"id":"https://openalex.org/keywords/thromboembolic-pulmonary-hypertension","display_name":"thromboembolic pulmonary hypertension","score":0.949999988079071},{"id":"https://openalex.org/keywords/treatment-selection","display_name":"treatment selection","score":0.4009999930858612},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5059999823570251},{"id":"https://openalex.org/keywords/mechanism-of-action","display_name":"mechanism of action","score":0.597000002861023}],"concepts":[{"id":"https://openalex.org/C2776432619","wikidata":"https://www.wikidata.org/wiki/Q3495231","display_name":"Treprostinil","level":3,"score":0.8642253279685974},{"id":"https://openalex.org/C2776304953","wikidata":"https://www.wikidata.org/wiki/Q2154494","display_name":"Riociguat","level":4,"score":0.700922966003418},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6979920268058777},{"id":"https://openalex.org/C2776345702","wikidata":"https://www.wikidata.org/wiki/Q390709","display_name":"Endothelin receptor antagonist","level":4,"score":0.5593072175979614},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5357498526573181},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44671791791915894},{"id":"https://openalex.org/C144980905","wikidata":"https://www.wikidata.org/wiki/Q24721308","display_name":"Endothelin receptor","level":3,"score":0.4141440987586975},{"id":"https://openalex.org/C2780930700","wikidata":"https://www.wikidata.org/wiki/Q1128595","display_name":"Pulmonary hypertension","level":2,"score":0.3785436749458313},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2542792558670044},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.18602284789085388},{"id":"https://openalex.org/C2777428986","wikidata":"https://www.wikidata.org/wiki/Q1958249","display_name":"Chronic thromboembolic pulmonary hypertension","level":3,"score":0.08828207850456238}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.21693/1933-088x-15.4.193","doi":"https://doi.org/10.21693/1933-088x-15.4.193","is_oa":true,"landing_page_url":"https://doi.org/10.21693/1933-088x-15.4.193","pdf_url":null,"source":{"id":"https://openalex.org/S4210197088","display_name":"Advances in Pulmonary Hypertension","issn_l":"1933-088X","issn":["1933-088X","1933-0898"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Pulmonary Hypertension","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.21693/1933-088x-15.4.193","doi":"https://doi.org/10.21693/1933-088x-15.4.193","is_oa":true,"landing_page_url":"https://doi.org/10.21693/1933-088x-15.4.193","pdf_url":null,"source":{"id":"https://openalex.org/S4210197088","display_name":"Advances in Pulmonary Hypertension","issn_l":"1933-088X","issn":["1933-088X","1933-0898"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Pulmonary Hypertension","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.7799999713897705}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W13250750","https://openalex.org/W2014889690","https://openalex.org/W2059635169","https://openalex.org/W2107011819","https://openalex.org/W2116338856","https://openalex.org/W2129282733","https://openalex.org/W2161450347","https://openalex.org/W2262036130","https://openalex.org/W2278696749","https://openalex.org/W2429455173","https://openalex.org/W2466807627","https://openalex.org/W2531336280","https://openalex.org/W2547646848","https://openalex.org/W2724626825","https://openalex.org/W4241487982","https://openalex.org/W6740573662"],"related_works":["https://openalex.org/W2236322344","https://openalex.org/W3004287417","https://openalex.org/W2187891509","https://openalex.org/W2766151889","https://openalex.org/W2091025049","https://openalex.org/W4391554615","https://openalex.org/W2964556716","https://openalex.org/W4226358904","https://openalex.org/W2618531184","https://openalex.org/W2231490797"],"abstract_inverted_index":{"The":[0],"availability":[1],"of":[2,8,32,43,52,78,102,204],"newer":[3,69],"oral":[4],"agents":[5,57],"for":[6,21,75,213],"therapy":[7,24,104],"pulmonary":[9,166],"arterial":[10],"hypertension":[11],"entails":[12],"both":[13],"opportunity":[14,20],"and":[15,25,50,95,112,139,180,209],"uncertainty.":[16],"There":[17],"is":[18,37,73,118],"the":[19,26,68,71,76,79,100,202,225],"less":[22],"intrusive":[23],"potential":[27],"to":[28,88,128,145,158,173,184,221],"further":[29],"lessen":[30],"risk":[31,51],"disease":[33],"progression,":[34],"but":[35],"there":[36],"also":[38,155,195],"uncertainty":[39],"regarding":[40],"optimal":[41],"role":[42],"these":[44,56,214],"agents,":[45,70,215],"concern":[46],"about":[47],"their":[48,222],"expense,":[49],"preventable":[53],"deterioration":[54],"if":[55],"are":[58],"used":[59,183],"in":[60,91,99,132,149,161,191],"settings":[61],"that":[62,124],"clearly":[63],"warrant":[64],"parenteral":[65,189],"prostanoids.":[66],"Among":[67],"evidence":[72],"strongest":[74],"use":[77],"prostacyclin":[80],"receptor":[81,115,137],"agonist":[82],"selexipag,":[83],"which":[84],"has":[85,125,154,170,181],"been":[86,126,156,171,182],"shown":[87,127,157,172],"reduce":[89],"events":[90],"functional":[92],"class":[93],"II":[94],"III":[96],"patients,":[97],"even":[98],"setting":[101],"background":[103],"with":[105,134,228],"a":[106,119,142,146,218],"phosphodiesterase":[107],"type":[108],"5":[109],"(PDE5)":[110],"inhibitor":[111,148],"an":[113,135],"endothelin":[114,136],"antagonist.":[116],"Riociguat":[117],"soluble":[120],"guanylate":[121],"cyclase":[122],"stimulator":[123],"be":[129,141,159],"beneficial,":[130],"including":[131],"combination":[133],"antagonist,":[138],"may":[140],"useful":[143],"alternative":[144],"PDE5":[147],"properly":[150],"selected":[151,193],"patients.":[152],"It":[153],"beneficial":[160],"inoperable":[162],"or":[163,188],"residual":[164],"thromboembolic":[165],"hypertension.":[167],"Oral":[168],"treprostinil":[169,190],"improve":[174],"6-minute":[175],"walk":[176],"distance":[177],"as":[178],"monotherapy,":[179],"transition":[185],"from":[186],"inhaled":[187],"carefully":[192],"patients":[194],"on":[196],"other":[197],"agents.":[198],"Herein":[199],"we":[200],"discuss":[201],"mechanisms":[203],"action,":[205],"side":[206],"effect":[207],"profiles,":[208],"clinical":[210],"trial":[211],"data":[212,227],"followed":[216],"by":[217],"practical":[219],"approach":[220],"use,":[223],"integrating":[224],"available":[226],"real-world":[229],"experience.":[230]},"counts_by_year":[],"updated_date":"2026-08-18T07:49:30.821534","created_date":"2017-08-17T00:00:00"}